Knight Therapeutics (GUD) Competitors C$5.23 +0.02 (+0.38%) (As of 01:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades GUD vs. TLRY, CRON, THCX, WEED, CPH, ACB, FIRE, EPI, OGI, and ICCShould you be buying Knight Therapeutics stock or one of its competitors? The main competitors of Knight Therapeutics include Tilray Brands (TLRY), Cronos Group (CRON), Hydropothecary (THCX), Canopy Growth (WEED), Cipher Pharmaceuticals (CPH), Aurora Cannabis (ACB), Supreme Cannabis (FIRE), ESSA Pharma (EPI), Organigram (OGI), and ICC Labs (ICC). These companies are all part of the "drug manufacturers - specialty & generic" industry. Knight Therapeutics vs. Tilray Brands Cronos Group Hydropothecary Canopy Growth Cipher Pharmaceuticals Aurora Cannabis Supreme Cannabis ESSA Pharma Organigram ICC Labs Tilray Brands (TSE:TLRY) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership, community ranking and dividends. Which has more risk and volatility, TLRY or GUD? Tilray Brands has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500. Comparatively, Knight Therapeutics has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Is TLRY or GUD more profitable? Knight Therapeutics has a net margin of -6.28% compared to Tilray Brands' net margin of -31.05%. Knight Therapeutics' return on equity of -2.70% beat Tilray Brands' return on equity.Company Net Margins Return on Equity Return on Assets Tilray Brands-31.05% -6.57% -1.41% Knight Therapeutics -6.28%-2.70%0.51% Do institutionals and insiders hold more shares of TLRY or GUD? 11.2% of Tilray Brands shares are held by institutional investors. Comparatively, 12.6% of Knight Therapeutics shares are held by institutional investors. 0.7% of Tilray Brands shares are held by company insiders. Comparatively, 45.6% of Knight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community prefer TLRY or GUD? Knight Therapeutics received 112 more outperform votes than Tilray Brands when rated by MarketBeat users. Likewise, 73.68% of users gave Knight Therapeutics an outperform vote while only 0.00% of users gave Tilray Brands an outperform vote. CompanyUnderperformOutperformTilray BrandsOutperform VotesNo VotesUnderperform Votes7100.00% Knight TherapeuticsOutperform Votes11273.68% Underperform Votes4026.32% Which has stronger earnings & valuation, TLRY or GUD? Knight Therapeutics has lower revenue, but higher earnings than Tilray Brands. Knight Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTilray BrandsC$788.94M2.01-C$244.98M-C$0.45-4.02Knight TherapeuticsC$337.87M1.56-C$21.23M-C$0.20-26.05 Does the media refer more to TLRY or GUD? In the previous week, Knight Therapeutics had 8 more articles in the media than Tilray Brands. MarketBeat recorded 12 mentions for Knight Therapeutics and 4 mentions for Tilray Brands. Knight Therapeutics' average media sentiment score of 0.88 beat Tilray Brands' score of -0.11 indicating that Knight Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tilray Brands 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Knight Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate TLRY or GUD? Tilray Brands currently has a consensus price target of C$2.95, indicating a potential upside of 62.98%. Knight Therapeutics has a consensus price target of C$7.08, indicating a potential upside of 35.96%. Given Tilray Brands' higher probable upside, analysts clearly believe Tilray Brands is more favorable than Knight Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tilray Brands 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Knight Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 SummaryKnight Therapeutics beats Tilray Brands on 14 of the 19 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Knight Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GUD vs. The Competition Export to ExcelMetricKnight TherapeuticsDrug Manufacturers IndustryMedical SectorTSE ExchangeMarket CapC$527.30MC$1.17BC$5.06BC$6.25BDividend YieldN/A3.13%4.97%5.27%P/E Ratio-26.05110.0289.0226.84Price / Sales1.561,819.041,207.281,531.29Price / Cash3.8510.4339.1783.81Price / Book0.693.116.083.15Net Income-C$21.23MC$159.31MC$119.07MC$299.38M7 Day Performance-0.19%-1.23%-1.84%0.76%1 Month Performance-7.13%-3.99%-3.65%12.82%1 Year Performance-2.43%87.52%31.62%44.03% Knight Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GUDKnight Therapeutics3.1727 of 5 starsC$5.23+0.4%C$7.08+35.4%-2.3%C$529.33MC$337.87M-26.15725Positive NewsTLRYTilray Brands0.5389 of 5 starsC$1.84+1.7%C$2.95+60.3%-27.3%C$1.61BC$788.94M-4.022,650News CoverageCRONCronos Group0.7933 of 5 starsC$2.85+2.2%C$3.18+11.6%-1.8%C$1.09BC$101.78M-13.29450THCXHydropothecaryN/AC$5.30+6.6%N/A+0.0%C$949.11MN/A0.00N/AHigh Trading VolumeWEEDCanopy Growth1.3326 of 5 starsC$5.50+4.4%C$7.12+29.4%+542.7%C$466.73MC$287.10M-0.672,700News CoverageCPHCipher Pharmaceuticals0.7615 of 5 starsC$14.52-1.4%C$12.50-13.9%+152.5%C$371.57MC$22.16M11.785ACBAurora Cannabis0.3829 of 5 starsC$6.03+1.3%C$5.69-5.7%+801.5%C$329.60MC$278.98M-9.441,073FIRESupreme CannabisN/AN/AN/AN/AC$255.58MC$53.29M-10.81400EPIESSA PharmaN/AC$8.20+7.2%N/A+0.0%C$237.87MN/A-8.2725OGIOrganigram3.0077 of 5 starsC$2.09+1.0%C$3.98+90.2%+16.3%C$226.91MC$149.21M-0.82987ICCICC LabsN/AC$1.62-5.8%N/A+0.0%C$223.64MC$533,684.0095.29N/AGap Up Related Companies and Tools Related Companies TLRY Alternatives CRON Alternatives THCX Alternatives WEED Alternatives CPH Alternatives ACB Alternatives FIRE Alternatives EPI Alternatives OGI Alternatives ICC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (TSE:GUD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
